SURMOUNT-1: tirzepatide achieved substantial, sustained weight reductions

A 72-week trial in people with obesity testing three weekly doses against placebo.

Tirzepatide acts on both GIP and GLP-1 receptors. In SURMOUNT-1, adults with obesity or overweight with comorbidities, without diabetes, received 5, 10 or 15 mg weekly or placebo for 72 weeks.

All three doses produced substantial and sustained weight reductions versus placebo, larger at higher doses. The most common adverse events were gastrointestinal, mostly mild or moderate.

In three points

Phase 3 human trial, 72 weeks
Substantial weight loss at all three doses
First dual GIP/GLP-1 agonist tested this way in obesity

Compounds mentioned

Tirzepatide

Original source: Tirzepatide Once Weekly for the Treatment of Obesity
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.